Comparison of Latanoprost PPDS With Timolol Maleate GFS in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Condition(s) targeted: Ocular Hypertension; Open-Angle Glaucoma

Intervention: Latanoprost Punctal Plug Delivery System (L-PPDS) (Drug); Timolol Maleate GFS, 0.5% (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Mati Therapeutics Inc.

Overall contact:
Tanya Steffan, Phone: 701-483-3599, Ext: 108, Email: tanyasteffan@trialrunners.com

Compare efficacy of the latanoprost punctal plug to timolol maleate ophthalmic gel forming solution (GFS) 0. 5% (administered once every morning). Effect of configuration of L-PPDS placement on efficacy will also be examined.

Official title: A Phase 2 Single-Masked, Randomized, Parallel Comparison of the Latanoprost Punctal Plug Delivery System (L-PPDS) With Timolol Maleate Ophthalmic Gel Forming Solution 0.5% in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: IOP change from baseline and the primary analysis time point will be the early morning assessment at Week 12

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Male or female, 18 years or older at the time of the screening examination 2. Subject diagnosed with bilateral OAG or OH 3. Subject IOP is currently controlled (< 21 mmHg) with a topical prostaglandin or in conjunction with one other topical ocular hypotensive drug, not including any fixed-combination formulations (i. e., Cosopt, Combigan, Azarga, etc.) for at least one month or more 4. Subject who has lower and upper puncta > 0. 5 mm and < 0. 9 mm (pre-dilation) in both eyes 5. Subject must be able and willing to read, comprehend and give Authorization for Use/Disclosure of Health Information (HIPAA) and informed consent 6. Subject must be willing to comply with study instructions, dosing (if applicable), agree to make all office appointments, and complete the entire course of the study 7. Women of child-bearing potential must not be pregnant or lactating, must have a negative pregnancy test at screening and must be practicing an adequate method of birth control, including intrauterine device (IUD); oral, dermal ("patch"), implant or injected contraceptives; tubal ligation; or barrier methods with spermicide 8. Subject has a central corneal thickness of > 500 μm and < 600 μm in study eye 9. Subject has a BCVA or pinhole visual acuity (Snellen) of 20/100 or better in both eyes Exclusion Criteria: 1. Subject with a history of non-response to topical prostaglandin eye drops for OAG/OH 2. Subject with angle-closure glaucoma, neovascular glaucoma, traumatic glaucoma or iridocorneal endothelium syndrome in either eye 3. Subject with a known sensitivity to latanoprost, timolol, fluorescein, topical anesthetic, silicone, any inactive ingredient of the L-PPDS or any other products required for the study procedures 4. Subject with a history of intolerance to topical beta-blocker therapy 5. Subject with > 0. 8 vertical cup or completely notched optic nerve head rim in either eye 6. Subject with any functionally significant visual field loss or progressive field loss within the last year in either eye 7. Subject with a history of complications, AEs, trauma or disease in the nasolacrimal area, whether or not it was due to punctal plug wear, including but not limited to dacryocystitis, inflammation or canaliculitis in study eye 8. Subject with structural lid abnormalities (i. e., ectropion, entropion) in study eye 9. Subject with an active lid disease in either eye (i. e., moderate or severe blepharitis, meibomianitis) that requires medical treatment 10. Subject with a history of chronic/recurrent inflammatory eye disease (i. e., scleritis, uveitis, herpes keratitis) in either eye 11. Subject who would require the use of any ocular topical medication(s), an over-the counter drop(s), ointment(s) or gel(s), other than the study ocular hypotensive medication(s) in either eye during the study period 12. Subject who has had any ophthalmic surgical procedures (i. e., glaucoma laser, minimally invasive glaucoma surgery, cataract, refractive, etc.) in study eye within the last six months or will require ophthalmic surgery before completing the study 13. Subject with a history of penetrating keratoplasty in study eye 14. Subject who is incapable of instilling ocular drops into his or her eyes 15. Subject requiring the use of a contact lens in either eye at any time during the study period 16. Subject with advanced diabetic retinopathy, branch retinal vein occlusion or central retinal vein occlusion in either eye 17. Subject with a history of macular edema in either eye 18. Subject currently on any systemic medication [i. e., beta-blocker, carbonic anhydrase inhibitors, corticosteroids (including dermal), etc.], that may have an effect on the subject's IOP, or who will require its use during the study period (Note: an inhaled steroid, systemic beta-blocker or β-adrenoceptor antagonist may be permitted, providing the subject has maintained a stable dosage regimen for at least the last three months) 19. Subject contraindicated to therapy with a beta-blocker (i. e., history or presence of bradycardia, untreated congestive heart failure, untreated second- or third-degree heart block, sino-atrial block, myasthenia gravis, cardiogenic shock, history or presence of bronchial asthma, bronchial hyperreactivity, severe chronic obstructive pulmonary disease, or history of bronchospasm) 20. Subject with an uncontrolled systemic disease or a medical condition that may increase the risk associated with study participation or administration of study treatment or that may interfere with the interpretation of study results (e. g., autoimmune disease if the subject is on chronic medications and has ocular involvement; host-versus-graft disease) 21. Subject currently participating or has participated within the last 30 days prior to the start of this study in a drug, device or other investigational research study

Tanya Steffan, Phone: 701-483-3599, Ext: 108, Email: tanyasteffan@trialrunners.com

Arizona Eye Center, Chandler, Arizona 85225, United States; Recruiting
Michael J. Depenbusch, MD

Arizona Glaucoma Specialists, Phoenix, Arizona 85050, United States; Recruiting
Max Kim, MD

Wolstan & Goldberg Eye Associates, Torrance, California 90505, United States; Recruiting
Damien F. Goldberg, MD

Argus Research at Cape Coral Eye Center, Cape Coral, Florida 33904, United States; Recruiting
Farrell C. Tyson, MD

Eye Associates of Fort Myers, Fort Myers, Florida 33901, United States; Recruiting
Stephen Smith, MD

Indiana Universtiy - Eugene and Marilyn Glick Eye Institute Ophthalmology Center, Indianapolis, Indiana 46202, United States; Recruiting
Darrell WuDunn, MD

Cincinnati Eye Institute, Edgewood, Kentucky 41017, United States; Recruiting
Edward Holland, MD

Great Lakes Eye Care, St. Joseph, Michigan 49085, United States; Recruiting
David L. Cooke, MD

Chu Vision Institute, Bloomington, Minnesota 55420, United States; Recruiting
Y. Ralph Chu, MD

Ophthalmology Associates, St. Louis, Missouri 63131, United States; Recruiting
Gregg Berdy, MD

Comprehensive Eye Care, Ltd., Washington, Missouri 63090, United States; Recruiting
Michael S. Korenfeld, MD

Abrams Eye Institute, Las Vegas, Nevada 89148, United States; Recruiting
Jack Abrams, MD

Ophthalmic Consultants of Long Island, Lynbrook, New York 11563, United States; Recruiting
Ronald M. Caronia, MD

Dr. Steven T. Simmons, Slingerlands, New York 12159, United States; Recruiting
Steven T. Simmons, MD

Philadelphia Eye Associates, Philadelphia, Pennsylvania 19148, United States; Recruiting
Carolyn Repke, MD

Wills Eye Hospital, Phildelphia, Pennsylvania 19107, United States; Recruiting
L. Jay Katz, MD

University Eye Surgeons, Maryville, Tennessee 37803, United States; Recruiting
Kenneth W. Olander, MD

Total Eye Care, Memphis, Tennessee 38119, United States; Recruiting
Eugene B. McLaurin, MD

Starting date: December 2013
Last updated: June 1, 2015